CASSS Sharing Science Solutions Mass Spectrometry 2025

CASSS Mass Spectrometry 2025 focuses on practical analytical work across biopharmaceutical discovery, development, quality control, and regulatory submissions. The September 24–26 program in Costa Mesa, California, covers LC-MS multi-attribute methods, therapeutic protein characterization, higher-order structure, and antigen–antibody interactions. Other sessions examine analytical challenges in ADCs, AAV, mRNA, oligonucleotides, and lipid nanoparticles, alongside automation and process monitoring. Presentations and roundtable discussions connect these methods with product quality and the needs of increasingly complex therapies. The course is aimed at mass spectrometrists, analytical scientists, development and QC teams, and regulatory professionals evaluating advanced characterization workflows.

Learning Objectives

Upon completion of this program, participants should be better able to:

• Implement and optimize LC-MS Multi-Attribute Method (MAM) workflows from research through to commercialization and QC.
• Evaluate antigen-antibody interactions and higher-order structures (HOS) using advanced MS and structural biology strategies.
• Characterize critical quality attributes (CQAs) of complex therapeutics, including mRNA, oligonucleotides, and intact AAV building blocks using individual ion MS.
• Apply electron activated dissociation (EAD) to identify reactive impurities, such as N-oxide in Lipid Nanoparticles (LNPs).
• Leverage MS analytical methods and platform knowledge to navigate FDA cell and gene therapy regulatory submissions.
• Integrate MS-based structural proteomics with molecular docking to analyze viral protein-host binding interfaces.

Topics

• A Robust and Versatile New Peak Detection Workflow to Facilitate the Implementation of the LC-MS Multi-Attribute Method (MAM) from Research to Commercialization

• Applications of Mass Spectrometry in Biopharmaceutical Discovery From Small Molecules to Proteins

• Automation and HTP Mass Spectrometry to Accelerate Biotherapeutics Discovery

• Best Practices for Elucidating Antibody Drug Conjugates Molecules by MS

• Best Practices of Extended Characterization Mass Spec Methods

• CASSS Welcome Mass Spec Introductory Comments

• Challenges and Obstacles to True Belonging in the Workplace

• Charge Variant Analysis of ANKTIVA N-803 using the Intabio ZT System Presented by SCIEX

• Closing Comments Invitation to Mass Spec 2026

• Combining In-Line Biocapacitance and LC-MS to Monitor and Understand Cell Culture Process in Real Time

• Diving Into the Complexities of Non-Natural Amino Acid Antibodies with Innovating Mass Spectrometry Approaches

• Employing Electron Activated Dissociation (EAD) fragmentation to identify reactive N-oxide impurities in Lipid Nanoparticles (LNPs)

• Evaluating Antigen-Antibody Interactions A Comparative Study of Higher-Order Structural MS Methods

• Expanding MAM Horizon Beyond mAb-Based Therapeutics

• High Throughput Sample Preparation Method for MS-Based Proteomics SPE Membrane Approaches for Peptide Cleanup and Enrichment

• Integrating Mass Spectrometry-Based Structural Proteomics and Molecular Docking to Analyze Ebola Protein-Host Binding Interfaces

• Keynote II – Advanced Mass Spectrometry and Structural Biology Strategies to Characterize Therapeutic Proteins

• LCMS Assays for mRNA CQAs A Development Story

• Leveraging Mass Spectrometry Analytical Methods in FDA Cell & Gene Therapy Regulatory Submissions Current Uses and Future Opportunities

• MAM in Development and in QC

• Mass Spec 2025 Poster Award & Poster Award Closing Remarks

• Mass Spec 2025 Scientific Program & Summary Infographic

• Mass Spec in Cell and Gene Therapy

• Mass Spectrometry & Predictive Stability

• Mass Spectrometry and Platform Knowledge Regulatory Strategies for Advanced Analytical Methods

• Mechanistic Insights Into Non-mAb Aggregation Using MS-Cleavable Linker

• Monitoring Intact AAV and AAV Building Blocks Through Individual Ion Mass Spectrometry

• MS for HCP

• MS of RNA and Oligonucleotides – Characterization and Quantitation of CQAs

• MS-Based Protein Higher Order Structure Characterization in Biologics Research and Development

• New Mass Spec Methods to Tackle New Biotherapeutic Challenges

• New Paradigm for Charge Variant Characterization Based on cIEF-MS and Discovery Assisted Fractionation Strategy

• Purpose-Built Software A Guided Analytical Workflow for the Multi-Attribute Method Presented by Agilent Technologies Inc

• Rapid Online Buffer Exchange with the DynaChip X1 Platform Enabling Simplified MS and CDMS Analysis of Large Biomolecules

• Session II – Mass Spectrometry in Cell and Gene Therapy

• Session III – MS Trends in Regulatory Research Review and Standard

• Session VII – Mass Spectrometry in Higher Order Structure

• Setting a New Standard in Biotherapeutic Characterization Holistic Multi-Attribute Characterization of a Bispecific Molecule Leveraging Fast

• Simplifying Every Stage of Your Biologics Development Journey From Advanced Characterization to Manufacturing Confidence

• Streamlining Agile MS Workflows with Genedata Expressionist

• Unleashing the Full Potential of High-Resolution Mass Spectrometry Presented by SCIEX

• Unraveling the Metabolic Regulatory Mechanisms Driving Lactate Runaway / Product Expression and Quality in CHO Cell Cultures Using a Multi-Omics Approach